Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Executive Summary

A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.


Related Content

Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
Which Biopharmas Are Best Positioned For Five-Year Growth?
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
When Will Gilead Make Its M&A Move?
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Full Access To HCV Drugs Would Save Money Long-Term, Study Finds
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
Merck Hep C Drug Zepatier OK'd


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts